Other

Centre National De La Recherche Scientifique

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Technische Universitaet Braunschweig

Technische Universitaet Carolo-wilhelmina Zu Braunschweig

Proqinase Gmbh

Develogen Atkiengesellschaft

Universitè{grave Over ( )} De Poitiers

Université De Poitiers

Technische Universitat Braunschweig

Develogen Aktiengesellschaft

Technische Universität Carolo Wilhelmina Zu Braunschweig

Conrad Kunick

Laurent Meijer

Christoph Schachtele

Edward A Sausville

Rick Gussio

Frédéric Becq

Frank Totzke

Ulrike Burk

Michael Kubbutat

Ravi Kumar Jalluri

Frederic Becq

Jan Ehlert

Marcus Geese

Hoang Lande

Rainer Mussmann

Simone Kegel

Johann Gruenefeld

Daniel W Zaharevitz

Hendrik Stukenbrock

Sebastian Wolfel

Ron Dzikowski

Holger Weber

Abed Nasereddin

Christoph SCHÄCHTELE

Sebastian WÖLFEL

In a first aspect, the present invention relates to new compounds as depicted in formula (I). In particular, compounds according to the present invention are bisindolylcyclobuten-dione-based structures having antiprotozoal activity. In a further aspect, pharmaceutical compositions containing the same are provided as well as the use of the compounds and pharmaceutical compositions for the prophylaxis and treatment of parasite based diseases including malaria. Finally, methods for the treatment of parasite diseases including malaria are provided. 

Indole compounds having antiprotozoal activity and its use as well as methods for producing the same

The present invention relates to thioether derivatives (1) as protein kinase inhibitors, which are useful for the treatment, relieve and/or prevention of diseases associated with abnormal and hyperproliferation of cells in a mammal, especially humans, and which are particularly useful for the treatment of all forms of cancer. 

Thioether derivatives as protein kinase inhibitors

This invention relates to the use of azapaullones, particularly in combination with immunomodulating agents, in the prevention, and/or treatment of pancreatic autoimmune disorders, e.g. type I diabetes or LADA and neurodegenerative disorders.

Use of azapaullones for preventing and treating pancreatic autoimmune disorders

The invention relates to paullone derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivatives being of general formula (1): wherein X&#x2550;C&#x2550;O, C&#x2014;S&#x2014;CH, C&#x2014;S, &#x2014;C&#x2014;NHOH, Z&#x2014;C or N, Y&#x2014; with the adjacent ring, a phenyl or thienyl group, the ring(s) of said derivatives being optionally substituted with one or more halogen atoms, hydroxy, alkylenehydroxy, alkynealkylenehydroxy, alkynehydroxycyclohexyl, alkyl, alkoxy, alkylenealkoxy, or alkylenecyano groups where the alkylene group is either saturated or unsaturated, the groups having a straight or branched chain with C1 to C18, said chain being optionally substituted with one or more hydroxy or amino groups, or one or more trifluoromethyl, &#x2014;COM, &#x2014;COOM, or &#x2014;CHCOOM groups (where M=H, C1 to C18 straight or branched chain alkyl, optionally substituted with one or more hydroxy and/or amino groups) nitroso, or cyano, R&#x2550;H, or C1 to C5 alkyl and R&#x2550;H, or &#x2014;C&#x2014;CO&#x2014;(CH)and the physiologically-acceptable salts and derivatives thereof.

Use of paullone derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells

The invention concerns the use for producing of GSK-3&#x3b2; inhibiting medicines from paullone derivatives. The invention is useful for treating pathologies involving GSK-3&#x3b2; and CDK5.

Use of paullone derivatives for making medicines

Fused azepinone cyclin dependent kinase inhibitors

Growing community of inventors

Hamburg, Germany

Conrad Kunick